Immunovant, Inc. IMVT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s EPS (diluted)?
- Immunovant, Inc. (IMVT) reported EPS (diluted) of -$0.73 in Q1 2026.
- How has Immunovant, Inc.'s EPS (diluted) changed year-over-year?
- Immunovant, Inc.'s EPS (diluted) decreased by 15.9% year-over-year, from -$0.63 to -$0.73.
- What is the long-term trend for Immunovant, Inc.'s EPS (diluted)?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EPS (diluted) has grown at a 18.1% compound annual growth rate (CAGR), from -$1.43 to -$2.78.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.